Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Atypical myopathy testing service launched
sycamore
Atypical myopathy is caused by the ingestion of sycamore tree seeds or seedlings, which contain the toxin hypoglycin-A.

RVC hopes to improve understanding of the condition 

Testing for atypical myopathy is now being offered by the RVC as part of its work to develop improved treatments and management of the disorder.

Atypical myopathy is a life-threatening equine muscle disorder caused by the ingestion of sycamore tree seeds or seedlings, which contain the toxin hypoglycin-A.

The risk factors for horses are unclear. For example, it is not known whether some trees are more toxic than others, or whether the toxin levels vary at certain times of the year, or in certain climates.

Scientists have developed a more rapid test for hypoglycin-A and its principal metabolite MCPA-carnitine. The Comparative Neuromuscular Diseases Laboratory at the RVC is now offering testing for the toxin and its metabolite in serum from horses suspected of having atypical myopathy, or at-risk field companions.

The RVC’s lab also offers urine organic acid and plasma acyl carnitine profile testing, which support the diagnosis in this acquired form of multiple acyl-coA dehydrogenase deficiency. Samples must be submitted by vets.

Samples of sycamore seeds, seedlings and leaves are also being tested for horse owners who have concerns about trees on their properties. Owners can organise this directly with the lab.

Professor Richard Piercy, professor of comparative neuromuscular disease, commented: “Through working with vets and owners in this way and with the support of the Horse Trust and [RVC’s Animal Care Trust], we hope to be able to improve the understanding of the condition and improve the welfare of horses.”

Image courtesy of RVC

 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.